{"id":"NCT01148524","sponsor":"Novartis Vaccines","briefTitle":"Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10","officialTitle":"A Phase 2b/3, Multi-Center, Extension Study of V72P10 to Assess Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-08","primaryCompletion":"2012-01","completion":"2012-01","firstPosted":"2010-06-22","resultsPosted":"2014-03-11","lastUpdate":"2018-06-15"},"enrollment":817,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Disease","Meningococcal Meningitis"],"interventions":[{"type":"BIOLOGICAL","name":"No Vaccine","otherNames":[]},{"type":"BIOLOGICAL","name":"rMenB+OMV-NZ","otherNames":["Serogroup B meningococcal recombinant vaccine"]}],"arms":[{"label":"rMenB06","type":"OTHER"},{"label":"rMenB0","type":"OTHER"},{"label":"rMenB016","type":"OTHER"},{"label":"rMenB01","type":"OTHER"},{"label":"rMenB026","type":"OTHER"},{"label":"rMenB02","type":"OTHER"},{"label":"rMenB012","type":"OTHER"},{"label":"rMenB6","type":"OTHER"},{"label":"Naive","type":"OTHER"}],"summary":"This was a Phase 2b/3, multi-center, extension study of V72P10 to assess antibody persistence at 18 months after the vaccination course in study V72P10 (NCT00661713).\n\nSubjects who participated in study V72P10, and who meet all other enrollment criteria for this extension study, and a group of naïve subjects (defined as subjects who had never received rMenB+OMV NZ or other experimental MenB vaccines) of similar age to the subjects who were eligible to participate in this extension study, performed one study visit in which a single blood sample was drawn for MenB serological analyses.","primaryOutcome":{"measure":"Percentage of Subjects With hSBA Titers ≥1:4 Against Meningococcal Strains, At 18 Months After Month-6 Vaccination in V72P10 Study, and in Naive Subjects.","timeFrame":"month 0 (bl=baseline), month 1 and 18 months after last vaccination in V72P10 study.","effectByArm":[{"arm":"rMenB06","deltaMin":31,"sd":null},{"arm":"rMenB0","deltaMin":40,"sd":null},{"arm":"rMenB016","deltaMin":40,"sd":null},{"arm":"rMenB01","deltaMin":32,"sd":null},{"arm":"rMenB026","deltaMin":32,"sd":null},{"arm":"rMenB02","deltaMin":41,"sd":null},{"arm":"rMenB012","deltaMin":44,"sd":null},{"arm":"rMenB6","deltaMin":47,"sd":null},{"arm":"Naive","deltaMin":null,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":6,"countries":["Chile"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":49},"commonTop":[]}}